Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
- 4.3 mg/kg of luveltamab tazevibulin ( luvelta ) in combination with standard dose of bevacizumab ( 15 mg/kg ) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose ...
| Ticker |
Sentiment |
Impact |
|
PCVX
|
Neutral
|
3 %
|
|
STRO
|
Neutral
|
13 %
|
